Agranulocytosis during malaria prophylaxis with Maloprim (pyrimethamine and dapsone)

Area of Science:

• Medical Science
• Pharmacology
• Infectious Disease Epidemiology

Background:

• Malaria prophylaxis is crucial for travelers and endemic populations.
• Maloprim (pyrimethamine and dapsone) is a commonly used antimalarial drug.
• The use of Maloprim is reportedly increasing in the context of evolving malaria prophylaxis strategies.

Observation:

• A case of agranulocytosis, a severe reduction in white blood cells, was observed.
• The agranulocytosis occurred in a patient undergoing malaria prophylaxis.
• The patient was taking Maloprim at the recommended dosage of one tablet weekly.

Findings:

• Agranulocytosis is a rare but significant adverse event associated with Maloprim.
• This case underscores a potential risk linked to the increasing use of Maloprim.
• The occurrence highlights the importance of monitoring for hematological side effects during antimalarial treatment.

Implications:

• Clinicians should be aware of the potential for agranulocytosis with Maloprim, even at recommended doses.
• Increased surveillance for adverse drug reactions is warranted as Maloprim use expands.
• This finding may influence future guidelines for malaria prophylaxis, especially in regions with changing malaria transmission patterns.